Table 1.
Description of baseline and 1-year characteristics associated with reported receipt of survivorship care planning by long-term (7-years) survivors.
| Characteristic | n (%) | Reported receipt of a written summary of cancer treatment and/or instructions on who to see for routine cancer fol ow-ups (N=832) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Unadjusted Percent (95% Confidence Interval)a | Adjusted Percent (95% Confidence Interval)c | ||||||||
| Received Neither (n=231) | Received Only One (n=391) | Received Both (n=210) | p-valueb | Received Neither (n=231) | Received Only One (n=391) | Received Both (n=210) | p-valued | ||
| Age in years | <0.0001 | 0.005 | |||||||
| ≤ 54 | 164 (19.7) | 20 (14-26) | 46 (39-54) | 34 (26-41) | 23 (17-30) | 44 (36-52) | 33 (25-40) | ||
| 55-64 | 252 (30.3) | 22 (17-27) | 50 (44-57) | 28 (22-33) | 22 (17-27) | 50 (43-56) | 28 (22-34) | ||
| 65-74 | 258 (31.0) | 28 (22-33) | 49 (43-55) | 23 (18-28) | 27 (21-32) | 49 (43-55) | 24 (19-29) | ||
| ≥ 75 | 158 (19.0) | 45 (37-53) | 39 (31-46) | 16 (11-22) | 41 (33-48) | 41 (33-48) | 19(13-25) | ||
| Gender | 0.833 | 0.775 | |||||||
| Male | 441 (53.0) | 28 (24-32) | 46 (41-51) | 26 (22-30) | 29 (25-33) | 46 (41-50) | 26 (22-30) | ||
| Female | 391 (47.0) | 27 (23-32) | 48 (43-53) | 25 (20-29) | 26 (22-31) | 47 (42-52) | 26 (22-31) | ||
| Race/ethnicity | 0.094 | 0.079 | |||||||
| White | 633 (76.2) | 28 (25-32) | 49 (45-53) | 23 (20-26) | 28 (24-31) | 49 (45-53) | 24 (20-27) | ||
| Hispanic | 22 (2.7) | 36 (16-56) | 36 (16-56) | 27 (9-46) | 33 (12-54) | 34 (13-55) | 33 (12-54) | ||
| Black | 105 (12.6) | 26 (17-34) | 38 (29-47) | 36 (27-45) | 30 (21-39) | 34 (25-43) | 37 (27-46) | ||
| Other | 71 (8.5) | 24 (14-34) | 46 (35-58) | 30 (19-40) | 22 (12-32) | 49 (37-61) | 29 (18-40) | ||
| Marital Status at 1 year | 0.345 | 0.771 | |||||||
| Married/living with partner | 582 (70.0) | 26 (23-30) | 48 (44-52) | 26 (22-29) | 27 (23-31) | 47 (43-51) | 26 (22-29) | ||
| Not married | 250 (30.0) | 31 (25-37) | 44 (38-51) | 24 (19-30) | 29 (23-35) | 45 (38-51) | 26 (21-32) | ||
| BMI at 1 year | 0.090 | 0.249 | |||||||
| Underweight/Normal | 210 (25.4) | 34 (28-41) | 43 (37-50) | 22 (17-28) | 33 (26-39) | 42 (35-49) | 26 (20-32) | ||
| Pre-obese | 316 (38.2) | 28 (23-33) | 47 (41-52) | 25 (21-30) | 28 (23-33) | 46 (40-51) | 26 (21-31) | ||
| Obese | 301 (36.4) | 23 (18-28) | 50 (44-55) | 27 (22-32) | 23 (18-28) | 50 (45-56) | 26 (21-31) | ||
| Alcohol Use (drinks per week)- 1-year survey | 0.632 | 0.512 | |||||||
| None | 367 (44.3) | 29 (25-34) | 46 (41-51) | 25 (20-29) | 31 (26-36) | 45 (40-50) | 24 (20-29) | ||
| >0 – < 7 | 324 (39.1) | 24 (20-29) | 50 (45-55) | 26 (21-30) | 24 (19-29) | 49 (44-55) | 26 (22-31) | ||
| 7-10.5 | 109 (13.1) | 31 (23-40) | 43 (34-52) | 26 (17-34) | 27 (18-35) | 43 (34-53) | 30 (22-39) | ||
| ≥ 17.5 | 29 (3.5) | 34 (17-52) | 38 (20-56) | 28 (11-44) | 30 (13-47) | 41 (23-60) | 28 (11-45) | ||
| Smoking Status at 1 year | 0.094 | 0.162 | |||||||
| Never | 281 (33.8) | 23 (19-28) | 51 (45-56) | 26 (21-31) | 24 (19-29) | 50 (44-56) | 26 (21-31) | ||
| Former | 410 (49.3) | 28 (24-33) | 47 (42-52) | 25 (21-29) | 28 (23-32) | 45 (41-50) | 27 (22-31) | ||
| Current | 55 (6.6) | 25 (14-37) | 44 (31-57) | 31 (19-43) | 27 (15-39) | 47 (34-61) | 26 (14-38) | ||
| Unknown | 86 (10.3) | 41 (30-51) | 38 (28-49) | 21 (12-30) | 40 (29-51) | 36 (25-47) | 24 (14-33) | ||
| Comorbidity Status at Diagnosis | 0.744 | 0.568 | |||||||
| None | 251 (30.2) | 26 (21-32) | 51 (45-57) | 23 (18-28) | 28 (23-34) | 50 (44-56) | 22 (16-27) | ||
| Mild | 351 (42.2) | 28 (24-33) | 44 (39-50) | 27 (23-32) | 28 (23-33) | 44 (38-49) | 29 (24-33) | ||
| Moderate | 148 (17.8) | 28 (20-35) | 46 (38-54) | 26 (19-33) | 26 (19-34) | 45 (36-53) | 29 (22-37) | ||
| Severe | 82 (9.9) | 30 (21-40) | 48 (37-58) | 22 (13-31) | 27 (17-37) | 49 (39-60) | 24 (14-33) | ||
| Cancer Type | 0.138 | 0.039 | |||||||
| Lung | 210 (25.2) | 28 (22-34) | 52 (45-59) | 20 (15-26) | 24 (18-30) | 56 (49-63) | 20 (15-26) | ||
| CRC | 622 (74.8) | 28 (24-31) | 45 (41-49) | 27 (23-30) | 29 (25-33) | 43 (39-47) | 28 (24-32) | ||
| Cancer Stage | 0.554 | 0.162 | |||||||
| Stage I | 367 (44.8) | 30 (26-35) | 45 (40-50) | 25 (21-30) | 29 (24-34) | 41 (36-46) | 30 (26-35) | ||
| Stage II | 206 (25.2) | 26 (20-32) | 48 (41-54) | 26 (20-32) | 24 (18-30) | 49 (42-56) | 26 (20-33) | ||
| Stage III | 218 (26.6) | 26 (20-31) | 49 (42-55) | 26 (20-31) | 29 (23-35) | 50 (44-57) | 21 (15-26) | ||
| Stage IV | 28 (3.4) | 14 (1-27) | 61 (43-79) | 25 (9-41) | 17 (3-31) | 64 (46-82) | 19 (4-34) | ||
| Had Radiation Treatment | 0.645 | 0.501 | |||||||
| Yes | 118 (14.2) | 29 (21-37) | 43 (34-52) | 28 (20-36) | 33 (29-36) | 43 (39-46) | 24 (21-28) | ||
| No | 714 (85.8) | 28 (24-31) | 48 (44-51) | 25 (22-28) | 27 (19-35) | 47 (38-56) | 26 (18-34) | ||
| Had Chemotherapy | 0.003 | 0.029 | |||||||
| Yes | 374 (45.0) | 23 (18-27) | 48 (43-53) | 30 (25-34) | 24 (20-28) | 44 (39-49) | 32 (28-37) | ||
| No | 458 (55.0) | 32 (28-36) | 47 (42-51) | 22 (18-25) | 30 (26-35) | 49 (43-54) | 21 (17-25) | ||
| Had Surgery | 0.819 | 0.395 | |||||||
| Yes | 778 (93.5) | 28 (24-31) | 47 (44-51) | 25 (22-28) | 28 (15-41) | 47 (32-61) | 26 (13-38) | ||
| No | 54 (6.5) | 31 (19-44) | 44 (31-58) | 24 (13-35) | 25 (22-28) | 39 (36-43) | 35 (32-39) | ||
| Quality of Cancer Care at 1 year | 0.012 | 0.215 | |||||||
| Excellent or Very Good | 677 (82.1) | 27 (24-30) | 47 (43-51) | 26 (23-30) | 27 (24-30) | 46 (42-50) | 27 (24-30) | ||
| Good | 112 (13.6) | 26 (18-34) | 52 (43-61) | 22 (15-30) | 25 (17-34) | 52 (43-62) | 22 (14-30) | ||
| Fair or poor | 36 (4.4) | 53 (36-69) | 28 (13-42) | 19 (7-32) | 43 (26-60) | 38 (22-54) | 19 (6-33) | ||
| Self-rated Health at 1 year | 0.023 | 0.170 | |||||||
| Excellent/Very Good | 419 (50.5) | 25 (21-29) | 50 (45-55) | 25 (21-29) | 26 (21-30) | 49 (45-54) | 25 (21-29) | ||
| Good | 278 (33.5) | 26 (21-31) | 49 (43-54) | 25 (20-30) | 27 (22-33) | 47 (41-53) | 26 (21-31) | ||
| Fair/Poor | 132 (15.9) | 38 (30-46) | 35 (27-43) | 27 (20-35) | 34 (26-42) | 35 (27-44) | 31 (23-39) | ||
a
Wald Confidence intervals;
b
Unadjusted Pearson chi-square value;
c
Extension of Graubard and Korn [13];
d
Wald chi-square p-value. Adjusted for study site, age, gender, race, marital status at 1 year, BMI at 1 year, drinks per week at 1 year, history of smoking at 1 year, cancer type, cancer stage, surgery, radiation, chemotherapy, quality of care at 1 year, self-rated health at 1 year.